Patents by Inventor Prakash SUNDARAMURTHI

Prakash SUNDARAMURTHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Medroxyprogesterone acetate injectable compositions and methods of use
    Patent number: 11911500
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml medroxyprogesterone acetate, 1.35 mg/ml to 1.65 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: February 27, 2024
    Assignee: Family Health International
    Inventor: Prakash Sundaramurthi
  • Medroxyprogesterone acetate injectable compositions and methods of use
    Patent number: 11752095
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 260 mg/ml to 440 mg/ml medroxyprogesterone acetate, about 0.6 mg/ml to 1.5 mg/ml docusate sodium and, polyethylene glycol. Methods of using these compositions are also described.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: September 12, 2023
    Assignee: Family Health International
    Inventors: Prakash Sundaramurthi, Ivana Mijakovac, Andrea Rasic, Iva Tunjic
  • MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE
    Publication number: 20220387448
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Application
    Filed: June 17, 2022
    Publication date: December 8, 2022
    Inventors: Prakash SUNDARAMURTHI, Ivana MIJAKOVAC
  • MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE
    Publication number: 20220105027
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 260 mg/ml to 440 mg/ml medroxyprogesterone acetate, about 0.6 mg/ml to 1.5 mg/ml docusate sodium and, polyethylene glycol. Methods of using these compositions are also described.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 7, 2022
    Inventors: Prakash SUNDARAMURTHI, Ivana MIJAKOVAC, Andrea RASIC, Iva TUNJIC
  • MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE
    Publication number: 20220047500
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml medroxyprogesterone acetate, 1.35 mg/ml to 1.65 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Application
    Filed: September 30, 2021
    Publication date: February 17, 2022
    Inventor: Prakash Sundaramurthi
  • Medroxyprogesterone acetate injectable compositions and methods of use
    Patent number: 11135154
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml medroxyprogesterone acetate, 1.35 mg/ml to 1.65 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 5, 2021
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventor: Prakash Sundaramurthi
  • MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE
    Publication number: 20200281939
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 10, 2020
    Inventors: Prakash SUNDARAMURTHI, Ivana MIJAKOVAC
  • MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE
    Publication number: 20190076352
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml medroxyprogesterone acetate, 1.35 mg/ml to 1.65 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Application
    Filed: March 2, 2017
    Publication date: March 14, 2019
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES
    Inventor: Prakash SUNDARAMURTHI